HYPERION DEFI INC (HYPD) Stock Price, Forecast & Analysis
USA - NASDAQ:HYPD - US30234E2037 - Common Stock
HYPD Key Statistics, Chart & Performance
The current stock price of HYPD is 4.97 USD. In the past month the price decreased by -34.08%.
HYPD Latest News, Press Relases and Analysis
HYPD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.84 | 974.90B | ||
| JNJ | JOHNSON & JOHNSON | 19.27 | 481.67B | ||
| MRK | MERCK & CO. INC. | 10.95 | 240.86B | ||
| PFE | PFIZER INC | 7.95 | 144.70B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.17 | 95.79B | ||
| ZTS | ZOETIS INC | 18.63 | 52.36B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.6 | 23.01B | ||
| VTRS | VIATRIS INC | 4.6 | 12.49B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.28 | 10.63B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.35 | 7.91B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.36B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.30B |
Related stock screener links
About HYPD
Company Profile
Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The firm is focused on providing simplified access to the Hyperliquid ecosystem. The company is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. The company has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.
Company Info
HYPERION DEFI INC
295 Madison Avenue, Suite 2400
New York City NEW YORK US
Employees: 13
Phone: 18333936684
HYPERION DEFI INC / HYPD FAQ
What does HYPD do?
Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The firm is focused on providing simplified access to the Hyperliquid ecosystem. The company is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. The company has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.
What is the current price of HYPD stock?
The current stock price of HYPD is 4.97 USD. The price increased by 16.94% in the last trading session.
Does HYPD stock pay dividends?
HYPD does not pay a dividend.
How is the ChartMill rating for HYPERION DEFI INC?
HYPD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the ownership structure of HYPERION DEFI INC (HYPD)?
You can find the ownership structure of HYPERION DEFI INC (HYPD) on the Ownership tab.
What is the outstanding short interest for HYPERION DEFI INC?
The outstanding short interest for HYPERION DEFI INC (HYPD) is 28.15% of its float.
HYPD Technical Analysis
HYPD Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HYPD. Both the profitability and financial health of HYPD have multiple concerns.
HYPD Financial Highlights
Over the last trailing twelve months HYPD reported a non-GAAP Earnings per Share(EPS) of -34.16. The EPS increased by 43.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -708.22% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HYPD Forecast & Estimates
For the next year, analysts expect an EPS growth of 33.51% and a revenue growth 400.98% for HYPD